{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:02:57Z","timestamp":1791291777940,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Project in the Science & Technology Program of Sichuan Province","award":["2022YFS0233"],"award-info":[{"award-number":["2022YFS0233"]}]},{"name":"Key Project in the Science & Technology Program of Sichuan Province","award":["2022YFS0225"],"award-info":[{"award-number":["2022YFS0225"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273556"],"award-info":[{"award-number":["82273556"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Project of \u20180 to 1\u2019 of Sichuan University","award":["2022SCUH0033"],"award-info":[{"award-number":["2022SCUH0033"]}]},{"name":"Med-X Center for Informatics Funding Project","award":["YGJC004"],"award-info":[{"award-number":["YGJC004"]}]},{"name":"the 1\u00b73\u00b75 Project for Disciplines of Excellence Clinical Research Incubation Project, West China Hospital of Sichuan University","award":["ZYJC21060"],"award-info":[{"award-number":["ZYJC21060"]}]},{"name":"the 1\u00b73\u00b75 Project for Disciplines of Excellence Clinical Research Incubation Project, West China Hospital of Sichuan University","award":["2020HXFH048"],"award-info":[{"award-number":["2020HXFH048"]}]},{"name":"the 1\u00b73\u00b75 Project for Disciplines of Excellence Clinical Research Incubation Project, West China Hospital of Sichuan University","award":["2019HXFH056"],"award-info":[{"award-number":["2019HXFH056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Patients with vascular anomalies (VAs) who receive oral sirolimus may be at high risk of infectious complications. Antibiotic prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMZ) has been advocated. However, there have been few evidence-based analyses on this topic. This study assessed the effect of prophylactic TMP-SMZ on the incidence of infections in VA patients receiving sirolimus monotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective, multicenter chart review was performed on all VA patients receiving sirolimus treatment from August, 2013 to January, 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Before January 2017, 112 patients were treated with sirolimus without antibiotic prophylaxis. In the subsequent period, 195 patients were treated with TMP-SMZ for at least 12\u00a0months during sirolimus therapy. The percentage of patients with at least one serious infection during the initial 12\u00a0months of sirolimus treatment did not differ between the groups (difference, 1.1%; 95% CI\u2009\u2212\u20097.0\u20138.0%). We observed no difference in the incidence of individual infection or total adverse events between the groups. The rate of sirolimus discontinuation due to adverse events did not differ significantly between groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We demonstrated that prophylactic TMP-SMZ does not decrease the incidence of infection or improve tolerance in VA patients receiving sirolimus monotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02740-3","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T04:06:59Z","timestamp":1684901219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral antibiotic prophylaxis for infection in patients with vascular anomalies receiving sirolimus treatment: a multicenter retrospective study"],"prefix":"10.1186","volume":"18","author":[{"given":"Tong","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuepeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuru","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiteng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9289-9660","authenticated-orcid":false,"given":"Yi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"issue":"1","key":"2740_CR1","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1542\/peds.2014-3673","volume":"136","author":"M Wassef","year":"2015","unstructured":"Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies. Pediatrics. 2015;136(1):e203-214.","journal-title":"Pediatrics"},{"issue":"7","key":"2740_CR2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1001\/archderm.144.7.873","volume":"144","author":"A Dompmartin","year":"2008","unstructured":"Dompmartin A, Acher A, Thibon P, Tourbach S, Hermans C, Deneys V, et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol. 2008;144(7):873\u20137.","journal-title":"Arch Dermatol"},{"issue":"2","key":"2740_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajmg.a.36836","volume":"167A","author":"KM Keppler-Noreuil","year":"2015","unstructured":"Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015;167A(2):287\u201395.","journal-title":"Am J Med Genet A"},{"key":"2740_CR4","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.2147\/CMAR.S171223","volume":"10","author":"Y Ji","year":"2018","unstructured":"Ji Y, Yang K, Chen S, Peng S, Lu G, Liu X. Musculoskeletal complication in kaposiform hemangioendothelioma without Kasabach\u2013Merritt phenomenon: clinical characteristics and management. Cancer Manag Res. 2018;10:3325\u201331.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"2740_CR5","first-page":"457","volume":"179","author":"Y Ji","year":"2018","unstructured":"Ji Y, Yang K, Peng S, Chen S, Xiang B, Xu Z, et al. Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach\u2013Merritt phenomenon. Br J Dermatol. 2018;179(2):457\u201363.","journal-title":"Br J Dermatol"},{"key":"2740_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.720611","volume":"10","author":"S Dai","year":"2022","unstructured":"Dai S, Yang K, Qiu T, Zhou J, Zhang X, Chen S, et al. Health-related quality of life in children with Kaposiform hemangioendothelioma. Front Pediatr. 2022;10: 720611.","journal-title":"Front Pediatr"},{"issue":"1","key":"2740_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13023-020-1320-1","volume":"15","author":"Y Ji","year":"2020","unstructured":"Ji Y, Chen S, Yang K, Xia C, Li L. Kaposiform hemangioendothelioma: current knowledge and future perspectives. Orphanet J Rare Dis. 2020;15(1):39.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 5","key":"2740_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bcpt.13027","volume":"123","author":"J Kangas","year":"2018","unstructured":"Kangas J, Natynki M, Eklund L. Development of molecular therapies for venous malformations. Basic Clin Pharmacol Toxicol. 2018;123(Suppl 5):6\u201319.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"2740_CR9","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.2021014027","volume":"139","author":"Y Ji","year":"2022","unstructured":"Ji Y, Chen S, Zhou J, Yang K, Zhang X, Xiang B, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for Kaposiform hemangioendothelioma: a randomized clinical trial. Blood. 2022;139(11):1619\u201330.","journal-title":"Blood"},{"issue":"11","key":"2740_CR10","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jamadermatol.2021.3459","volume":"157","author":"A Maruani","year":"2021","unstructured":"Maruani A, Tavernier E, Boccara O, Mazereeuw-Hautier J, Leducq S, Bessis D, et al. Sirolimus (rapamycin) for slow-flow malformations in children: The observational-phase randomized clinical PERFORMUS trial. JAMA Dermatol. 2021;157(11):1289\u201398.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2740_CR11","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jvs.2021.04.071","volume":"74","author":"Y Ji","year":"2021","unstructured":"Ji Y, Chen S, Yang K, Zhou J, Zhang X, Jiang X, et al. A prospective multicenter study of sirolimus for complicated vascular anomalies. J Vasc Surg. 2021;74(5):1673\u201381.","journal-title":"J Vasc Surg"},{"issue":"1","key":"2740_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jvs.2019.06.217","volume":"71","author":"C Freixo","year":"2020","unstructured":"Freixo C, Ferreira V, Martins J, Almeida R, Caldeira D, Rosa M, et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review. J Vasc Surg. 2020;71(1):318\u201327.","journal-title":"J Vasc Surg"},{"issue":"1","key":"2740_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-019-1118-1","volume":"14","author":"M Ozeki","year":"2019","unstructured":"Ozeki M, Nozawa A, Yasue S, Endo S, Asada R, Hashimoto H, et al. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies. Orphanet J Rare Dis. 2019;14(1):141.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2740_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13023-018-0934-z","volume":"13","author":"J Hammer","year":"2018","unstructured":"Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, et al. Sirolimus is efficacious in treatment for extensive and\/or complex slow-flow vascular malformations: a monocentric prospective phase II study. Orphanet J Rare Dis. 2018;13(1):191.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2740_CR15","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ijc.30775","volume":"141","author":"Y Ji","year":"2017","unstructured":"Ji Y, Chen S, Xiang B, Li K, Xu Z, Yao W, et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study. Int J Cancer. 2017;141(4):848\u201355.","journal-title":"Int J Cancer"},{"issue":"2","key":"2740_CR16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3257","volume":"137","author":"DM Adams","year":"2016","unstructured":"Adams DM, Trenor CC 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2): e20153257.","journal-title":"Pediatrics"},{"issue":"Suppl 5","key":"2740_CR17","doi-asserted-by":"publisher","first-page":"S421","DOI":"10.1542\/peds.2017-1044","volume":"141","author":"TB Russell","year":"2018","unstructured":"Russell TB, Rinker EK, Dillingham CS, Givner LB, McLean TW. Pneumocystis jirovecii pneumonia during sirolimus therapy for Kaposiform hemangioendothelioma. Pediatrics. 2018;141(Suppl 5):S421\u20134.","journal-title":"Pediatrics"},{"issue":"Suppl 5","key":"2740_CR18","doi-asserted-by":"publisher","first-page":"S425","DOI":"10.1542\/peds.2016-2919","volume":"141","author":"H Ying","year":"2018","unstructured":"Ying H, Qiao C, Yang X, Lin X. A case report of 2 sirolimus-related deaths among infants with Kaposiform hemangioendotheliomas. Pediatrics. 2018;141(Suppl 5):S425\u20139.","journal-title":"Pediatrics"},{"issue":"1","key":"2740_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13023-021-01893-3","volume":"16","author":"J Zhou","year":"2021","unstructured":"Zhou J, Yang K, Chen S, Ji Y. Sirolimus in the treatment of kaposiform lymphangiomatosis. Orphanet J Rare Dis. 2021;16(1):260.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2740_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/MPH.0000000000000771","volume":"39","author":"R Proudfoot","year":"2017","unstructured":"Proudfoot R, Phillips B, Wilne S. Guidelines for the prophylaxis of Pneumocystis jirovecii pneumonia (PJP) in children with solid tumors. J Pediatr Hematol Oncol. 2017;39(3):194\u2013202.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"2740_CR21","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1016\/S2214-109X(17)30143-2","volume":"5","author":"S Lockman","year":"2017","unstructured":"Lockman S, Hughes M, Powis K, Ajibola G, Bennett K, Moyo S, et al. Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled trial. Lancet Glob Health. 2017;5(5):e491\u2013500.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"2740_CR22","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1097\/MPH.0000000000001650","volume":"42","author":"A Nozawa","year":"2020","unstructured":"Nozawa A, Ozeki M, Yasue S, Endo S, Kawamoto N, Ohnishi H, et al. Immunologic effects of sirolimus in patients with vascular anomalies. J Pediatr Hematol Oncol. 2020;42(5):e355\u201360.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"2740_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28936","volume":"68","author":"J Rossler","year":"2021","unstructured":"Rossler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M, et al. Severe adverse events during sirolimus \u201coff-label\u201d therapy for vascular anomalies. Pediatr Blood Cancer. 2021;68(8): e28936.","journal-title":"Pediatr Blood Cancer"},{"key":"2740_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.101999","volume":"67","author":"T Otani","year":"2021","unstructured":"Otani T, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, et al. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: a retrospective cohort study. Pulm Pharmacol Ther. 2021;67: 101999.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"2740_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/TP.0b013e31829e2723","volume":"96","author":"RK Patel","year":"2013","unstructured":"Patel RK, Taylor A, Jardine AG. Prophylactic ciprofloxacin for kidney transplant recipients\u2014to add or not to add. Transplantation. 2013;96(4):370\u20131.","journal-title":"Transplantation"},{"issue":"1","key":"2740_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/infdis\/jiw482","volume":"215","author":"CV Hobbs","year":"2017","unstructured":"Hobbs CV, Anderson C, Neal J, Sahu T, Conteh S, Voza T, et al. Trimethoprim-sulfamethoxazole prophylaxis during live malaria sporozoite immunization induces long-lived, homologous, and heterologous protective immunity against sporozoite challenge. J Infect Dis. 2017;215(1):122\u201330.","journal-title":"J Infect Dis"},{"issue":"5","key":"2740_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77(5):644\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2740_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13075-019-1996-6","volume":"21","author":"JW Park","year":"2019","unstructured":"Park JW, Curtis JR, Kim MJ, Lee H, Song YW, Lee EB. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. Arthritis Res Ther. 2019;21(1):207.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"2740_CR29","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/cncr.2820360912","volume":"36","author":"WT Hughes","year":"1975","unstructured":"Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO, Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer. 1975;36(6):2004\u20139.","journal-title":"Cancer"},{"issue":"11","key":"2740_CR30","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/jamadermatol.2017.2808","volume":"153","author":"KT Amber","year":"2017","unstructured":"Amber KT, Lamberts A, Solimani F, Agnoletti AF, Didona D, Euverman I, et al. Determining the incidence of pneumocystis pneumonia in patients with autoimmune blistering diseases not receiving routine prophylaxis. JAMA Dermatol. 2017;153(11):1137\u201341.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2740_CR31","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jvsv.2021.03.014","volume":"9","author":"YJ Cho","year":"2021","unstructured":"Cho YJ, Kwon H, Kwon YJ, Kim SC, Kim DY, Namgoong JM. Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: a single-center experience. J Vasc Surg Venous Lymphat Disord. 2021;9(6):1488\u201394.","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"6","key":"2740_CR32","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1111\/bcp.15202","volume":"88","author":"VEM Harbers","year":"2022","unstructured":"Harbers VEM, van der Salm N, Pegge SAH, van der Vleuten CJM, Verhoeven BH, Vrancken SLAG, et al. Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach\u2013Merritt phenomenon in young infants. Br J Clin Pharmacol. 2022;88(6):2769\u201381.","journal-title":"Br J Clin Pharmacol"},{"key":"2740_CR33","doi-asserted-by":"publisher","first-page":"e29603","DOI":"10.1002\/pbc.29603","volume":"69","author":"KA Shimano","year":"2022","unstructured":"Shimano KA, Eng W, Adams DM. How we approach the use of sirolimus and new agents: medical therapy to treat vascular anomalies. Pediatr Blood Cancer. 2022;69:e29603.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2740_CR34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","volume":"161","author":"JW Park","year":"2022","unstructured":"Park JW, Curtis JR, Jun KI, Kim TM, Heo DS, Ha J, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab. Chest. 2022;161(5):1201\u201310.","journal-title":"Chest"},{"issue":"10","key":"2740_CR35","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","volume":"126","author":"D Gianfreda","year":"2015","unstructured":"Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G, et al. Sirolimus plus prednisone for Erdheim\u2013Chester disease: an open-label trial. Blood. 2015;126(10):1163\u201371.","journal-title":"Blood"},{"issue":"1","key":"2740_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28036","volume":"67","author":"I Iacobas","year":"2020","unstructured":"Iacobas I, Adams DM, Pimpalwar S, Phung T, Blei F, Burrows P, et al. Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus. Pediatr Blood Cancer. 2020;67(1): e28036.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2740_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/MPH.0000000000000804","volume":"39","author":"HF Nazir","year":"2017","unstructured":"Nazir HF, Elshinawy M, AlRawas A, Khater D, Zadjaly S, Wali Y. Efficacy and safety of dapsone versus trimethoprim\/sulfamethoxazol for Pneumocystis jiroveci prophylaxis in children with acute lymphoblastic leukemia with a background of ethnic neutropenia. J Pediatr Hematol Oncol. 2017;39(3):203\u20138.","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02740-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02740-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02740-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T04:07:40Z","timestamp":1684901260000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02740-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2740"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02740-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee on medical research of West China Hospital, Sichuan University and was conducted in accordance with the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}